Cempra to Present at the Cowen and Company 36th Annual Healthcare Conference
February 29, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Fourth Quarter and Full Year 2015 Financial Results
February 17, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics in the face of rising antibiotic...
Paratek Accelerates Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 3 Skin Trial
January 06, 2016 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that it projects its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the...
Melinta Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference
January 05, 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that Dr. Eugene Sun, the Company’s interim Chief Executive Officer, will be providing a corporate update at...
Cempra Doses First Patient in Phase 3 Clinical Trial of Taksta(TM) in Acute Bacterial Skin and Skin Structure Infections
December 08, 2015 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company developing antibiotics to meet critical medical needs in the treatment of...
Melinta Therapeutics Presents Complete Delafloxacin Results from Phase 3 Study in Patients with Acute Bacterial Skin and Skin Structure Infections at ID Week
October 09, 2015 15:30 ET
|
Melinta Therapeutics
NEW HAVEN, CT and SAN DIEGO, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, today announced...
Cempra to Present Solithromycin Data at ID Week 2015
October 05, 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Solithromycin Data in COPD Patient Subgroup at European Respiratory Society International Congress
September 24, 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
FDA Grants Qualified Infectious Disease Product Designation to Taksta(TM) Cempra's Fusidic Acid Antibiotic
September 18, 2015 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Melinta Therapeutics Joins White House Forum on Antibiotic Stewardship in Commitment to Take Steps to Avert Potential Crisis
June 02, 2015 07:30 ET
|
Melinta Therapeutics
New Haven, CT, June 2, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today it is joining with more
than 150 other major food companies, retailers, and human and
animal health stakeholders at...